{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:31:20Z","timestamp":1787725880987,"version":"build-2784847793"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is associated with uremic-related platelet dysfunction and a greater risk of perioperative bleeding. Desmopressin (DDAVP) is believed to improve platelet function and is used prophylactically to prevent post-operative bleeding, but with uncertain efficacy. In this research, we evaluated the efficacy of peri-procedural desmopressin administration in reducing bleeding complications in CKD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Scopus, and Embase up to August 2025 for randomized controlled trials (RCTs) and observational studies involving adult CKD patients undergoing non-surgical procedures who received peri-procedural desmopressin compared to a control group. Outcomes included overall bleeding events, hematoma, hematuria, hematocrit decline, transfusions, and interventions for bleeding control. Safety profile of hyponatremia was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1,744 records, a total of 7,944 participants from 21 studies were included. The meta-analysis showed that desmopressin did not significantly reduce overall bleeding events (OR 0.87, 95% CI 0.57\u20131.33). Similarly, there was no significant effect on the incidence of hematoma (OR 1.35, 95% CI 0.40\u20134.53) or hematuria (OR 1.44, 95% CI 0.50\u20134.12). Subgroup analysis restricted to randomized controlled trials (RCTs) demonstrated a significant reduction in overall bleeding events with desmopressin (OR 0.50, 95% CI 0.29\u20130.87). Further subgroup analysis by route of administration revealed that the intranasal route was associated with a significant reduction in total bleeding events (OR 0.52, 95% CI 0.32\u20130.84).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that desmopressin does not significantly reduce post-procedural bleeding in CKD patients. However, subgroup analyses restricted to RCTs, and the intranasal administration route suggest a reduction in bleeding complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO ID: CRD420251118342, URL:\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251118342<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1857125","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:03:47Z","timestamp":1787724227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of desmopressin in reducing post-procedural bleeding among chronic kidney disease patients: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Chananchida","family":"Sirilertmekasakul","sequence":"first","affiliation":[{"name":"Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Porpim","family":"Jindasakchai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudapree","family":"Sorasuchart","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society","place":["Bangkok, Thailand"]},{"name":"Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanat","family":"Lertussavavivat","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suramath","family":"Isaranuwatchai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.3390\/ijms25168705","article-title":"Hallmarks for thrombotic and hemorrhagic risks in chronic kidney disease patients","volume":"25","author":"Saeed","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1681\/asn.0000000000000199","article-title":"The crosstalk between nephropathy and coagulation disorder: pathogenesis, treatment, and dilemmas","volume":"34","author":"Qiu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1681\/asn.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/pgmj.2006.052118","article-title":"How do you treat bleeding disorders with desmopressin?","volume":"83","author":"Ozg\u00f6nenel","year":"2007","journal-title":"Postgrad Med J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0167-4889(90)90058-l","article-title":"DDAVP-induced release of von Willebrand factor from endothelial cells in vitro: the effect of plasma and blood cells","volume":"1052","author":"Hashemi","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4103\/ijn.IJN_553_20","article-title":"Desmopressin acetate before percutaneous ultrasound-guided kidney biopsy in patients with renal failure is it really beneficial?","volume":"32","author":"Jose","year":"2022","journal-title":"Indian J Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ckj\/sfz114","article-title":"Intranasal desmopressin reduces renal biopsy-related bleeding and serum sodium levels in patients with reduced renal function","volume":"13","author":"Rao","year":"2020","journal-title":"Clin Kidney J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2010.12.019","article-title":"Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial","volume":"57","author":"Manno","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13741-023-00358-4","article-title":"Desmopressin to reduce periprocedural bleeding and transfusion: a systematic review and meta-analysis","volume":"13","author":"Wang","year":"2024","journal-title":"Perioper Med (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM198301063080102","article-title":"Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia","volume":"308","author":"Mannucci","year":"1983","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/ds.DS-D-22-00154","article-title":"Using grading of recommendations assessment, development, and evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: a quick tutorial","volume":"41","author":"Shao","year":"2023","journal-title":"Dermatol Sin"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12882-019-1595-4","article-title":"Desmopressin and bleeding risk after percutaneous kidney biopsy","volume":"20","author":"Athavale","year":"2019","journal-title":"BMC Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"03000605211040764","DOI":"10.1177\/03000605211040764","article-title":"Safety of renal biopsy bleeding prophylaxis with desmopressin","volume":"49","author":"Sosa Barrios","year":"2021","journal-title":"J Int Med Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/healthcare13131553","article-title":"The role of fixed-dose desmopressin in hemostatic outcomes of native and transplant kidney biopsies in a tertiary referral hospital","volume":"13","author":"Bifari","year":"2025","journal-title":"Healthcare"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.nefroe.2020.12.008","article-title":"No effect of desmopressin administration before kidney biopsy on the risk of major post-biopsy bleeding","volume":"42","author":"Cheong","year":"2022","journal-title":"Nefrologia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.47102\/annals-acadmedsg.2019164","article-title":"Bleeding complications and adverse events after desmopressin acetate for percutaneous renal transplant biopsy","volume":"49","author":"Ho","year":"2020","journal-title":"Ann Acad Med Singap"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00277-015-2384-1","article-title":"Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ekir.2020.05.006","article-title":"Use of desmopressin prior to kidney biopsy in patients with high bleeding risk","volume":"5","author":"Leclerc","year":"2020","journal-title":"Kidney Int Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s11255-019-02155-9","article-title":"Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia","volume":"51","author":"Lim","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/01.laboratory.0000154043.28615.01","article-title":"Should renal insufficiency be a relative contraindication to bronchoscopic biopsy?","volume":"12","author":"Mehta","year":"2005","journal-title":"J Bronchology Interv Pulmonol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/nep.13004","article-title":"Desmopressin (Octostim) before a native kidney biopsy can reduce the risk for biopsy complications in patients with impaired renal function: a pilot study","volume":"23","author":"Peters","year":"2018","journal-title":"Nephrology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1177\/0284185120910590","article-title":"Renal transplant biopsy complications: assessment of risk factors and potential of desmopressin to decrease risk of hemorrhage","volume":"61","author":"Peters","year":"2020","journal-title":"Acta Radiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s11255-022-03143-2","article-title":"Native kidney biopsies in older adults: disease spectrum, long-term kidney and patient survival and safety","volume":"54","author":"Tan","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s1051-0443(91)72272-0","article-title":"A 5-year experience with 307 CT-guided renal biopsies: results and complications","volume":"2","author":"Sateriale","year":"1991","journal-title":"J Vasc Interv Radiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.14423\/SMJ.0000000000000578","article-title":"Transfusion requirements in ESRD patients admitted with GI hemorrhage undergoing inpatient endoscopy","volume":"109","author":"McCartney","year":"2016","journal-title":"South Med J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.34067\/KID.0000000760","article-title":"Effect of desmopressin on post kidney biopsy bleeding complications in patients with reduced kidney function: a randomized controlled trial","volume":"6","author":"Chakrabarti","year":"2025","journal-title":"Kidney360"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.ekir.2025.04.019","article-title":"Randomized double-blind placebo-controlled trial of desmopressin for post-kidney biopsy bleeding","volume":"10","author":"Prasad","year":"2025","journal-title":"Kidney Int Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.52547\/ijkd.6966","article-title":"Desmopressin acetate in percutaneous ultrasound-guided native kidney biopsy in patients with reduced kidney function: a double-blind randomized controlled trial","volume":"16","author":"Sattari","year":"2022","journal-title":"Iran J Kidney Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4103\/ijn.ijn_34_23","article-title":"Role of desmopressin acetate before percutaneous ultrasound-guided kidney biopsy in patients with kidney dysfunction","volume":"34","author":"Sethi","year":"2024","journal-title":"Indian J Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2549775","DOI":"10.1080\/0886022x.2025.2549775","article-title":"Desmopressin and bleeding risk in high-risk native kidney biopsy: updated meta-analysis of RCTs and observational studies","volume":"47","author":"Sartori Pacini","year":"2025","journal-title":"Ren Fail"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/jth.15653","article-title":"Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease","volume":"20","author":"Abdelmaguid","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1857125\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:03:47Z","timestamp":1787724227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1857125\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1857125"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1857125","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1857125"}}